Press Releases

Press Releases

IVI and Sweden renew partnership to accelerate vaccines for global public health

IVI to lead critical standard reagents availability for oral cholera vaccine manufacturing to ensure their uniform efficacy and help meet global demand

IVI appoints three new members to its Board of Trustees

IVI to Accelerate Efforts in iNTS Vaccine Development

IVI acquires GCLP certification from Korean Ministry of Food and Drug Safety

IVI Awarded $4.5 Million Grant to Increase Accessibility of Oral Cholera Vaccine

IVI Discusses Expanding Support for Global Collaboration on Vaccine R&D and Delivery with Top Foreign Diplomats in Seoul

IVI-led Consortium Awarded Fleming Fund Regional Grant to Improve Data Sharing in Fight against Antimicrobial Resistance

IVI to help developing countries tackle the spread of infectious diseases by building capacity through vaccinology training in Seoul

IVI acquires supplemental funding for Severe Typhoid in Africa Program (SETA Plus)

IVI Director General Dr. Jerome Kim to join the Human Vaccines Project’s Efforts as One of Four Distinguished Global Leaders to Decode the Human Immune System

Prof. Young Chul Sung, biotech leader, personally donates US$8.4 million to IVI

New push to develop world’s first vaccine against the deadly Strep A bacteria killing hundreds of thousand

IVI-led CAPTURA consortium wins Fleming Fund award for work on antimicrobial resistance (AMR) data across Asia

IVI receives $15.7 million grant to conduct phase III trials of new Vi-DT typhoid conjugate vaccine manufactured by SK bioscience of Korea

‘IVI Forum for Enhancement of Cooperation’ hosted jointly by the Korean Parliamentary Forum for Global Health, and KCDC under MOHW

Vaccine study confirms sensitivity of cholera test

Korean Pediatric Association, IVI, KSC exchange MOU

IVI receives $3.2 million grant to support TCV effectiveness studies in West Africa

CEPI partners with IVI to accelerate development of vaccines against emerging global health threats

Henry Lau joins IVI as Goodwill Ambassador

Nature Communications study addresses MDR typhoid

THSTI, IVI held joint symposium on Nov. 22

‘The Euvichol story’ published in Vaccine

IVI accelerates development of MERS vaccine

IVI’s 18th Vaccinology Course gathers 120 international participants from 19 countries in Seoul September 3-7

KOICA, IVI team up with Mozambican MoH and INS, partners to vaccinate 190,000 people against cholera

IVI acquires $5 million grant to support process development, scale up of typhoid conjugate vaccine with SK Bioscience


2015 Shinil-IVI Global Vaccine Forum: Int'l MERS-CoV Symposium on September 10, 2015

2016-10-10 02:13





2015 Shinil-IVI Global Vaccine Forum:


International MERS-CoV Symposium


10th September 2015


Champagne Hall, Novotel Ambassador Gangnam, Seoul, Republic of Korea




Overview: Scientists from the Republic of Korea, East Asia, Middle East, United States and Europe will present the latest translational and clinical research data, and discuss research opportunities related to Middle East Respiratory Syndrome (MERS), an emerging viral disease caused by Middle East Respiratory Syndrome Coronavirus (MERS-CoV) that is responsible for severe acute respiratory infection in more than 1,000 people across 25 countries. The need for vaccine development will be discussed as zoonotic outbreaks are likely to happen again and could lead to more serious epidemics.




08.30-09.00           Registration / Refreshments







09.00-09.10          Dr. Jerome Kim, Director General, International Vaccine Institute (IVI)


09.10-09.20          Prof. Wan-Kyoo Cho, Executive Advisor, Korea Support Committee for IVI





SESSION 1: Surveillance and Epidemiologic Investigation


Moderator                Dr. Youngmee Jee (Korea National Institute of Health) and


                                  Prof. Joon-Haeng Rhee (Chonnam National University Medical School, Korea)




09.20-09.40          Evolution of the MERS-CoV Outbreak in the Republic of Korea


                           Dr. Jerome Kim, International Vaccine Institute




09.40-10.00          Challenges and Successes in Controlling MERS-CoV in the Kingdom of Saudi Arabia


Dr. Abdulaziz Abdullah Bin Saeed, Ministry of Health, Kingdom of Saudi Arabia




10.00-10.20          The Role of International Normative Bodies in Anticipating Outbreaks


Dr. Kayvon Modjarrad on behalf of WHO, Walter Reed Army Institute of Research, USA




10.20-10.40          Q&A




10.40-11.00          Break / Press Conference





SESSION 2: Vaccines and Monoclonal Antibodies


Moderator                Prof. Baiklin Seong (Yonsei University, Korea) and


                                  Dr. Laura Digilio (International Vaccine Institute)




11.00-11.20          An Integrated Approach to Developing MERS-CoV Vaccines and mAbs


                           Dr. Kayvon Modjarrad, Walter Reed Army Institute of Research, USA




11.20-11.40          A Spike Nanoparticle MERS-CoV Vaccine


Mr. Russell P. Wilson, Novavax, USA




11.40-12.00          DNA Vaccine for MERS-CoV


                           Dr. Scott White, Inovio Pharmaceuticals, USA




12.00-12.10         Clinical Development of a DNA-based MERS Vaccine: Opportunities and Challenges


                           Dr. Joel Maslow, GeneOne Life Science, Inc., Korea




12.10-12.30          Q&A









12.30-12.45          H.E. Mark W. Lippert, U.S. Ambassador to the Republic of Korea, Embassy of the United States, Seoul




12.45-12.55          Group Photo




12.55-14.00          Lunch at The Square 





SESSION 3: Diagnostics and Therapeutics


Moderator                Prof. Daesub Song (Korea University, Korea) and


                                  Dr. In Kyu Yoon (International Vaccine Institute)




14.00-14.20         Identification of Potent Neutralizing Antibodies against MERS-CoV


                           Dr. Christos Kyratsous, Regeneron, USA




14.20-14.40          Use of Diagnostics to Aid in Identification of MERS-CoV Cases


                           Dr. Susan Gerber, Centers for Disease Control and Prevention, USA




14.40-15.00          Developing Viral Fusion Inhibitors for Prevention and Treatment of MERS-CoV Infection


Prof. Shibo Jiang, Fudan University, China




15.00-15.20          MERS-CoV: Opportunity for Drug Discovery in Korea to Complement Vaccine Development


Dr. Ji-Young Min, Institut Pasteur Korea, Korea  




15.20-15.40          Q&A




15.40-16.00          Break





SESSION 4: Clinical Considerations and Public Health Preparedness


Moderator                Dr. Stephen C. Redd (Centers for Disease Control and Prevention, USA) and


                                  Dr. Jean-Louis Excler (International Vaccine Institute)




16.00-16.20          Clinical Progression and Viral Load Kinetics of Middle East Respiratory Syndrome Coronavirus Infection


                           Prof. Myoung-don Oh, Seoul National University College of Medicine, Korea




16.20-16.40          Principle of MERS-CoV Infection Control: Saudi Arabia


                           Dr. Mark Beatty, Consultant, USA




16.40-17.00          Laboratory Preparedness in the Setting of an Outbreak


Dr. Bart Haagmans, Erasmus Medical Center, The Netherlands




17.00-17.20          Q&A




17.20-17.30          Closing Remarks










The symposium was organized by the MERS-CoV Symposium Scientific Committee: Kayvon Modjarrad, MHRP/WRAIR, USA;


James Hayslett, CDC/OPHPR/OD, USA; Jae-Ouk Kim, IVI; Jae Seung Yang, IVI; Ayan Dey, IVI; Florian Marks, IVI; Laura Digilio, IVI; Manki Song, IVI; Jerome Kim, IVI








We gratefully acknowledge Shinil and the Korea Support Committee for IVI (KSC) for their support.






Register at: